Description
Megamet VG 0.3 Tablets (10’s) | Glimepiride 2mg + Voglibose 0.3mg + Metformin SR 500mg | Advanced Triple Therapy for Type 2 Diabetes
Category: Anti-diabetic Combination Therapy
Pack Size: 10 Sustained-Release Tablets (Blister Pack)
Composition (Per Tablet):
-
Glimepiride 2mg (Third-generation Sulfonylurea – Insulin Secretagogue)
-
Voglibose 0.3mg (Alpha-Glucosidase Inhibitor – Postprandial Glucose Control)
-
Metformin SR 500mg (Sustained-Release Biguanide – Insulin Sensitizer)
Key Benefits:
✔️ Enhanced Postprandial Control: Higher strength voglibose (0.3mg) for better carbohydrate management
✔️ GI-Friendly Formulation: SR metformin minimizes gastrointestinal discomfort
✔️ Triple-Action Efficacy: Targets insulin secretion, resistance, and carbohydrate absorption
✔️ Once-Daily Convenience: Sustained-release technology for 24-hour coverage
Therapeutic Uses:
• Type 2 diabetes mellitus with significant postprandial hyperglycemia
• Patients uncontrolled on dual therapy regimens
• Those requiring focused post-meal glucose management
• Individuals intolerant to immediate-release metformin
Dosage (Adults):
-
1 tablet once daily with the first main meal
-
Swallow whole – do not crush, break, or chew
-
Maximum Dose: 2 tablets daily (under medical supervision)
Safety Profile:
🚫 Contraindications:
-
Type 1 diabetes mellitus
-
Diabetic ketoacidosis
-
Severe renal impairment (eGFR <30 mL/min)
-
Hepatic dysfunction
-
Gastrointestinal obstructions
⚠️ Monitor For:
• Hypoglycemia (especially during initial therapy)
• Gastrointestinal effects (flatulence, diarrhea)
• Liver function parameters
• Vitamin B12 levels (long-term use)
Drug Interactions:
▲ Significant Interactions:
-
Digestive enzyme preparations (reduced voglibose efficacy)
-
Beta-blockers (mask hypoglycemia symptoms)
-
Corticosteroids (diminished glycemic control)
Storage:
-
Store below 30°C
-
Protect from moisture and light
-
Keep in original blister packaging
Reviews
There are no reviews yet.